Business

Teva's Schultz Sees Stability Ahead for US Biosimilar, Generic Marketplace

January 15th 2020

By Mary Caffrey

The leading generic drug manufacturer launched Truxima, a biosimilar for rituximab, in November 2019 at a 10% discount to the reference product, Rituxan.

Gilead Touts New Products in Revamped Growth Strategy

January 15th 2020

By Tony Hagen

Gilead Science’s new chairman and chief executive officer outlined a growth plan this week at the J.P. Morgan Healthcare Conference in San Francisco, California.

US Biosimilar Launches, Stymied by Manufacturer Opposition, Continue to Struggle, Analysis Finds

January 14th 2020

By Tony Hagen

In the United States, recent analyses show that biosimilars achieved just 9%, or $91 million, of the $1 billion in cost savings that the Congressional Budget Office projected 10 years ago.

ICER Releases Final Report on JAK Inhibitors for Rheumatoid Arthritis

January 13th 2020

By Deana Ferreri, PhD

The final report includes voting results from a December 2019 meeting of one of ICER’s independent evidence appraisal panels, the California Technology Assessment Forum (CTAF), plus policy recommendations from an expert roundtable.

"Not So Different": Employers Advocate for Lower Drug Costs Through Biosimilars

January 13th 2020

With pharmaceutical spending at record levels, employers are looking for solutions and are hopeful that biosimilars can play a role in controlling costs. On this episode, we speak with representatives of EmployersRX, a new coalition made up of 3 employer groups that are advocating for measures that would provide relief for the largest purchasers of healthcare.

Bio-Thera Solutions' Biosimilar Adalimumab Launches in China

January 10th 2020

By The Center for Biosimilars Staff

It is the first adalimumab biosimilar approved by the China National Medical Products Administration.

Lobbying Group Appeals Decision Allowing California Pay-for-Delay Law to Take Effect

January 9th 2020

By The Center for Biosimilars Staff

The law made California the first state to bar pay-for-delay pharmaceutical agreements by making them presumptively anticompetitive if the nonreference drug maker receives anything of value from the other company.

IVI Updates RA Value Assessment Model to Include Biosimilars, Sarilumab, JAK Inhibitors

January 9th 2020

By The Center for Biosimilars Staff

The Innovation and Value Initiative (IVI) has updated its existing prototype economic model examining value among rheumatoid arthritis (RA) therapies to include biosimilars.

Novo Nordisk Launches Authorized Generic Insulins, Gets FDA Approval for Fast-Acting Insulin in Pediatric Population

January 7th 2020

By Allison Inserro

Novo Nordisk said 3 measures to make insulin more affordable are now available, and it also announced that the FDA expanded use of its fast-acting mealtime insulin to children as young as 2.

Pfizer Launches Bevacizumab Biosimilar, Zirabev, in the United States

January 6th 2020

By Allison Inserro

Zirabev, which references Avastin, will be priced at a wholesale acquisition cost (WAC) of $61.34 per 10 mg, representing a 23% discount to the WAC of Avastin, Pfizer said.